We are happy to share that Cambridge Cancer Genomics has been acquired by Dante Labs, a leading genomics and diagnostics company born in L’Aquila and now based in Cambridge, with offices in L’Aquila, New York, Dubai, and Wolverhampton. CCG.ai is a startup leader in machine learning for clinical oncology: the acquisition will allow Dante Labs to create a single platform with unparalleled capabilities in genomics and oncology data analysis.
CCG.ai was founded in 2016 by John Cassidy, Harry Clifford, and Nirmesh Patel to ensure that each patient has the right drug, at the right time, to beat their cancer. The team built software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. Pi Campus invested in CCG.ai in 2017, right after we met them at Y Combinator Demo Day.
“Matching cancer patients to the best therapy has been a longstanding problem in the field of oncology,” says Cassidy, CEO of the company, “Since we started working on CCG.ai, our team has dedicated themselves to state-of-the-art software development and fundamental research in tumor evolution, treatment response, and AI., to enable better deployment of targeted therapies for all. Now, with Dante Lab’s commercial reach and expertise in direct-to-consumer genomic testing, our products will be even closer to where they can make the ultimate impact, in the lives of patients.”
Till now, the broad adoption of precision medicine has been limited by the lack of integration of technology and biology in a single platform. With this acquisition of CCG.ai, Dante Lab states the company will now be able to provide clinical organizations with end-to-end oncology solutions to make decisions that have an impact on the lives of the patients.
